Developer docs
API playgroundTry for free, no card

Search company profiles

Biosyn

Full company profile

uuid0024612

Namestring
Biosyn
Legal namestring
biosyn Corporation
Websiteurl
biosyncorp.com
Company typeenum
Private
Founded yearint
1994
Descriptiontext

Biosyn Corporation is a privately held biopharmaceutical company founded in 1984 in Germany and incorporated in the United States in 1994/1995, headquartered in Carlsbad, California. The company specializes in the manufacture of Keyhole Limpet Hemocyanin (KLH) and Immunocyanin products derived from the hemolymph of the Giant Keyhole Limpet (Megathura crenulata) using proprietary non-lethal extraction, mariculture/aquaculture, GMP-grade purification, and lyophilization processes. Its core product portfolio spans IMMUCOTHEL® (the first hemocyanin product approved for bladder cancer immunotherapy, marketed in the Netherlands, Austria, Argentina, and South Korea), VACMUNE® (a KLH carrier protein for vaccine manufacture and immunology research), Native KLH (multiple research and GMP grades), the newer Reassociated Native KLH (RANKLH) launched in 2023 for conjugate vaccine manufacturers, and Selenase® (sodium selenite pentahydrate), a selenium drug product registered in 18+ countries and under FDA Drug Master File in the United States.

The company operates a fully validated GMP facility in Carlsbad, CA (completed 2001) including specialized aquaria for non-lethal handling of Giant Keyhole Limpets, and a wholly-owned German manufacturing subsidiary, biosyn Arzneimittel GmbH in Fellbach, where final GMP KLH products are finished. Revenue is generated through direct, sales-led enterprise engagement with pharmaceutical and academic research customers — including 3 of the 10 largest global pharmaceutical companies — via quote-based, multi-year contracts for bulk and vialed hemocyanin and selenium products in research and clinical/GMP grades. Pricing is not publicly disclosed. The company also provides regulatory and scientific support to customers using its products in investigational and commercial applications across multiple jurisdictions. Leadership rests with Dr. S.N. Muddukrishna as President and CEO; Mark O'Reilly is identified as a Managing Partner. No public ticker, funding rounds, or cap-table information is disclosed.

Short descriptiontext

Biosyn Corporation is a privately held biopharmaceutical company that manufactures clinical/GMP and research-grade Keyhole Limpet Hemocyanin (KLH) products and the selenium drug Selenase® for bladder cancer immunotherapy, vaccine manufacture, and selenium deficiency treatment across 18+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCarlsbad, United States
HQ citystring
Carlsbad
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
hemocyanin manufacturing, immunotherapy products, vaccine carrier proteins, selenium pharmaceuticals, biopharmaceutical products
Industry1 code
PRIMARYHLAMAEAD
Parasiticides & Ectoparasite Control (Flea/Tick/Heartworm)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Medicinal and Botanical Manufacturing325411
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Manufacturing
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Sales of hemocyanin/immunocyanin products
TypeHardware Sales
Description

Sales of KLH products (IMMUCOTHEL®, VACMUNE®, Native KLH, Reassociated KLH) in research grade and clinical/GMP grade formats, available as bulk and vialed products for investigational study use or non-clinical uses requiring GMP grade material.

biosyncorp.com
2Licensed drug product sales (Selenase®)
TypeLicensing Royalties
Description

Sales of selenase® (sodium selenite pentahydrate), registered as a drug product in more than 18 countries (Europe, Russia, Asia, South America) for selenium deficiency. In the U.S., marketed as an investigational product only.

biosyncorp.com
3Regulatory and scientific support services
TypeProfessional Services
Description

Provision of scientific and regulatory support to customers using biosyn hemocyanin products for research and development, supporting investigational and commercial purposes across global jurisdictions.

biosyncorp.com
Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1Quote-based pricing on bulk and vial-sized hemocyanin and selenium investigational products; no public list price.
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed. Available formats include Immucothel® 1mg, Vacmune® Liquid (bulk and 20mg vials, GMP and Research Grade), Vacmune® Powder (1mg and 10mg vials, Research Grade).

biosyncorp.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1IMMUCOTHEL®
Description

biosyn's proprietary Immunocyanin (KLH subunit) lyophilized formulation developed for bladder cancer treatment; marketed in the Netherlands, Austria, Argentina and South Korea.

biosyncorp.com
+4 more records
Core offering1 text field

Biosyn Corporation manufactures clinical/GMP and research grade Keyhole Limpet Hemocyanin (KLH) and Immunocyanin products derived from the hemolymph of Megathura crenulata (Giant Keyhole Limpet), marketed under the trade names IMMUCOTHEL®, VACMUNE®, Native KLH, and Reassociated KLH (RANKLH). The company also manufactures Selenase® (sodium selenite pentahydrate), a selenium drug product indicated for selenium deficiency and investigated in sepsis, intensive care, and other clinical settings. Products are sold as bulk and vialed clinical/research materials for immunotherapy, antibody production, vaccine adjuvant, and pharmaceutical use.

Differentiator
Functional benefit
Problem solved
Product and service5 records
1IMMUCOTHEL®
CategoryImmunotherapy / Biopharmaceutical
Description

Biosyn's proprietary lyophilized Immunocyanin (Keyhole Limpet Immunocyanin / KLI, ~400 kDa subunit) formulation developed for bladder cancer immunotherapy. It was the first hemocyanin product approved for the treatment of bladder cancer and is currently marketed in the Netherlands, Austria, Argentina and South Korea.

2VACMUNE®
CategoryVaccine carrier / Research reagent
Description

Biosyn's Immunocyanin (KLH subunits) offered as a carrier protein for vaccine manufacture, antibody production, and other immunological research applications. Available in liquid (IEX GMP Grade and Research Grade) and powder (Research Grade) forms, packaged as bulk and 1 mg, 10 mg, and 20 mg vials.

3Biosyn Native KLH
CategoryResearch / Clinical reagent
Description

Native Keyhole Limpet Hemocyanin derived from the hemolymph of Megathura crenulata (Giant Keyhole Limpet). Sold in multiple grades — GMP Grade, Research Grade, High Purity / Low Endotoxin Research Grade, and Low Endotoxin Research Grade — for use in immunotherapy, antibody production, immunology research, vaccine adjuvant, neoantigen, and immune status evaluation applications.

4Reassociated Native KLH (RANKLH) — High Molecular Weight Research Grade
CategoryResearch-grade KLH formulation
Description

A biosyn product consisting of KLH subunits reassociated after an intermediate virus filtration step, formulated in phosphate buffered saline at ~10 mg/mL. Designed to overcome the limitations of virus filtration on native KLH and to serve as a well-defined alternative KLH formulation for conjugate vaccine manufacturers; GMP Grade available on request.

5Selenase® (sodium selenite pentahydrate)
CategorySelenium drug product
Description

Biosyn's selenium product (sodium selenite pentahydrate), oral and injectable, registered as a drug product in more than 18 countries across Europe, Russia, Asia, and South America and indicated for selenium deficiency. In the U.S., it is marketed as an investigational product only, supported by an FDA Drug Master File; used in investigations for intensive care, sepsis, cardiosurgery, resuscitation, plastic surgery, organ transplantation and vascular surgery. Available in 1,000 µg dose vials for high-dose clinical usage.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Microbiology and immunoassay company with adjuvants and carrier protein adjacencies. Comparable in the sense of building GMP immuno-diagnostic and immunotherapy reagent portfolios that touch KLH-adjacent value chains (vaccines, immunology research).

TypeBroad incumbent
Description

Global contract development and manufacturing organization with biologics and cell-and-gene therapy capabilities. Comparable as a GMP biomanufacturing peer that pharma customers use for similar upstream and downstream processing of immunotherapy and vaccine products.

TypeOthers
Description

Supplies purification, filtration, and bioprocessing technologies that biosyn uses in KLH manufacturing. An ecosystem/equipment peer rather than a direct competitor, but relevant for understanding biosyn's manufacturing cost structure and GMP supply chain.

TypeRegional player
Description

German-rooted biopharmaceutical company developing mistletoe-based and other complementary oncology therapies. Comparable to biosyn's German subsidiary in jurisdiction and to IMMUCOTHEL®'s bladder cancer immunotherapy positioning in the European oncology market.

TypeDirect peer
Description

Supplies proteins and reagents (including antibodies and immunology research tools) used in immunotherapy and vaccine research workflows that consume KLH. Closely comparable customer base (academic and pharma immunology labs) to biosyn's research-grade KLH buyers.

TypeBroad incumbent
Description

Global life-sciences tools company that distributes Keyhole Limpet Hemocyanin as part of its research reagents catalog. Overlaps with biosyn's Native KLH and VACMUNE® research-grade offerings but operates across a vastly broader portfolio and is not specialized in GMP-grade hemocyanin.

TypeRegional player
Description

European specialty injectable pharmaceutical manufacturer with trace element and electrolyte products. Directly comparable to Selenase® in product category, route of administration, and European hospital market positioning.

8MilliporeSigma (Merck KGaA Life Science)
TypeBroad incumbent
Description

Supplies KLH (including Imject mcKLH) as a research reagent and carrier protein under the legacy Sigma-Aldrich brand. Directly comparable to biosyn's Native KLH and VACMUNE® research-grade products, but as part of a much broader life-sciences catalog rather than a GMP-focused manufacturer.

TypeBroad incumbent
Description

Major specialty/sterile injectable pharmaceutical manufacturer with a broad trace element and clinical nutrition portfolio that overlaps with biosyn's Selenase® injectable selenium franchise. Comparable in product format and hospital channel, though Fresenius operates at much larger scale.

TypeDirect peer
Description

Historically a direct competitor focused on sustainable KLH production from Megathura crenulata for immunotherapy and conjugate vaccine applications. Most directly comparable to biosyn in species, product format, and target market, though its current operating status is limited.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biosyn

Biopharmaceutical Manufacturingbiosyncorp.com

Biosyn Corporation is a privately held biopharmaceutical company that manufactures clinical/GMP and research-grade Keyhole Limpet Hemocyanin (KLH) products and the selenium drug Selenase® for bladder cancer immunotherapy, vaccine manufacture, and selenium deficiency treatment across 18+ countries.

What Biosyn does

Biosyn Corporation is a privately held biopharmaceutical company founded in 1984 in Germany and incorporated in the United States in 1994/1995, headquartered in Carlsbad, California. The company specializes in the manufacture of Keyhole Limpet Hemocyanin (KLH) and Immunocyanin products derived from the hemolymph of the Giant Keyhole Limpet (Megathura crenulata) using proprietary non-lethal extraction, mariculture/aquaculture, GMP-grade purification, and lyophilization processes. Its core product portfolio spans IMMUCOTHEL® (the first hemocyanin product approved for bladder cancer immunotherapy, marketed in the Netherlands, Austria, Argentina, and South Korea), VACMUNE® (a KLH carrier protein for vaccine manufacture and immunology research), Native KLH (multiple research and GMP grades), the newer Reassociated Native KLH (RANKLH) launched in 2023 for conjugate vaccine manufacturers, and Selenase® (sodium selenite pentahydrate), a selenium drug product registered in 18+ countries and under FDA Drug Master File in the United States.

The company operates a fully validated GMP facility in Carlsbad, CA (completed 2001) including specialized aquaria for non-lethal handling of Giant Keyhole Limpets, and a wholly-owned German manufacturing subsidiary, biosyn Arzneimittel GmbH in Fellbach, where final GMP KLH products are finished. Revenue is generated through direct, sales-led enterprise engagement with pharmaceutical and academic research customers — including 3 of the 10 largest global pharmaceutical companies — via quote-based, multi-year contracts for bulk and vialed hemocyanin and selenium products in research and clinical/GMP grades. Pricing is not publicly disclosed. The company also provides regulatory and scientific support to customers using its products in investigational and commercial applications across multiple jurisdictions. Leadership rests with Dr. S.N. Muddukrishna as President and CEO; Mark O'Reilly is identified as a Managing Partner. No public ticker, funding rounds, or cap-table information is disclosed.

Biosyn firmographics

Firmographics
Name
Biosyn
Legal name
biosyn Corporation
Website
https://biosyncorp.com
Company type
Private
Founded year
1994
Operating status
Operating
Headcount range
11–50 employees
Short description
Biosyn Corporation is a privately held biopharmaceutical company that manufactures clinical/GMP and research-grade Keyhole Limpet Hemocyanin (KLH) products and the selenium drug Selenase® for bladder cancer immunotherapy, vaccine manufacture, and selenium deficiency treatment across 18+ countries.
Ownership category
akta.pro rank

Biosyn industry classification

Industry
Product category
Biopharmaceutical Manufacturing
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Medicinal and Botanical Manufacturing (325411)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAMAEAD
Parasiticides & Ectoparasite Control (Flea/Tick/Heartworm)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics

Keywords

  • Hemocyanin manufacturing
  • Immunotherapy products
  • Vaccine carrier proteins
  • Selenium pharmaceuticals
  • Biopharmaceutical products

Where Biosyn is headquartered

Location

Headquarters

HQ city
Carlsbad
HQ country
United States
HQ region
North America

Markets served

Biosyn business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Sales of hemocyanin/immunocyanin products: Sales of KLH products (IMMUCOTHEL®, VACMUNE®, Native KLH, Reassociated KLH) in research grade and clinical/GMP grade formats, available as bulk and vialed products for investigational study use or non-clinical uses requiring GMP grade material.
  2. Licensed drug product sales (Selenase®): Sales of selenase® (sodium selenite pentahydrate), registered as a drug product in more than 18 countries (Europe, Russia, Asia, South America) for selenium deficiency. In the U.S., marketed as an investigational product only.
  3. Regulatory and scientific support services: Provision of scientific and regulatory support to customers using biosyn hemocyanin products for research and development, supporting investigational and commercial purposes across global jurisdictions.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based pricing on bulk and vial-sized hemocyanin and selenium investigational products; no public list price.

Go-to-market motion2 records

Biosyn product offering

Product offering

Core offering

Biosyn Corporation manufactures clinical/GMP and research grade Keyhole Limpet Hemocyanin (KLH) and Immunocyanin products derived from the hemolymph of Megathura crenulata (Giant Keyhole Limpet), marketed under the trade names IMMUCOTHEL®, VACMUNE®, Native KLH, and Reassociated KLH (RANKLH). The company also manufactures Selenase® (sodium selenite pentahydrate), a selenium drug product indicated for selenium deficiency and investigated in sepsis, intensive care, and other clinical settings. Products are sold as bulk and vialed clinical/research materials for immunotherapy, antibody production, vaccine adjuvant, and pharmaceutical use.

Differentiator

Problem solved

Functional benefit

Brands

  • IMMUCOTHEL®: biosyn's proprietary Immunocyanin (KLH subunit) lyophilized formulation developed for bladder cancer treatment; marketed in the Netherlands, Austria, Argentina and South Korea.
  • VACMUNE®
  • Native KLH
  • Reassociated KLH (RANKLH)
  • Selenase®

Products and services

  • IMMUCOTHEL® Biosyn's proprietary lyophilized Immunocyanin (Keyhole Limpet Immunocyanin / KLI, ~400 kDa subunit) formulation developed for bladder cancer immunotherapy. It was the first hemocyanin product approved for the treatment of bladder cancer and is currently marketed in the Netherlands, Austria, Argentina and South Korea.
  • VACMUNE® Biosyn's Immunocyanin (KLH subunits) offered as a carrier protein for vaccine manufacture, antibody production, and other immunological research applications. Available in liquid (IEX GMP Grade and Research Grade) and powder (Research Grade) forms, packaged as bulk and 1 mg, 10 mg, and 20 mg vials.
  • Biosyn Native KLH Native Keyhole Limpet Hemocyanin derived from the hemolymph of Megathura crenulata (Giant Keyhole Limpet). Sold in multiple grades — GMP Grade, Research Grade, High Purity / Low Endotoxin Research Grade, and Low Endotoxin Research Grade — for use in immunotherapy, antibody production, immunology research, vaccine adjuvant, neoantigen, and immune status evaluation applications.
  • Reassociated Native KLH (RANKLH) — High Molecular Weight Research Grade A biosyn product consisting of KLH subunits reassociated after an intermediate virus filtration step, formulated in phosphate buffered saline at ~10 mg/mL. Designed to overcome the limitations of virus filtration on native KLH and to serve as a well-defined alternative KLH formulation for conjugate vaccine manufacturers; GMP Grade available on request.
  • Selenase® (sodium selenite pentahydrate) Biosyn's selenium product (sodium selenite pentahydrate), oral and injectable, registered as a drug product in more than 18 countries across Europe, Russia, Asia, and South America and indicated for selenium deficiency. In the U.S., it is marketed as an investigational product only, supported by an FDA Drug Master File; used in investigations for intensive care, sepsis, cardiosurgery, resuscitation, plastic surgery, organ transplantation and vascular surgery. Available in 1,000 µg dose vials for high-dose clinical usage.

Companies that use Biosyn

Customer profile

Ideal customer profiles3 records

Biosyn technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Biosyn partnerships and signals

Strategic signal

Recent moves7 records

Expansion highlights4 records

Biosyn competitors and assessment

Company assessment

Emerging players

  • bioMérieux: Microbiology and immunoassay company with adjuvants and carrier protein adjacencies. Comparable in the sense of building GMP immuno-diagnostic and immunotherapy reagent portfolios that touch KLH-adjacent value chains (vaccines, immunology research).

Broad incumbents

  • Lonza Group: Global contract development and manufacturing organization with biologics and cell-and-gene therapy capabilities. Comparable as a GMP biomanufacturing peer that pharma customers use for similar upstream and downstream processing of immunotherapy and vaccine products.
  • Thermo Fisher Scientific: Global life-sciences tools company that distributes Keyhole Limpet Hemocyanin as part of its research reagents catalog. Overlaps with biosyn's Native KLH and VACMUNE® research-grade offerings but operates across a vastly broader portfolio and is not specialized in GMP-grade hemocyanin.
  • MilliporeSigma (Merck KGaA Life Science): Supplies KLH (including Imject mcKLH) as a research reagent and carrier protein under the legacy Sigma-Aldrich brand. Directly comparable to biosyn's Native KLH and VACMUNE® research-grade products, but as part of a much broader life-sciences catalog rather than a GMP-focused manufacturer.
  • Fresenius Kabi: Major specialty/sterile injectable pharmaceutical manufacturer with a broad trace element and clinical nutrition portfolio that overlaps with biosyn's Selenase® injectable selenium franchise. Comparable in product format and hospital channel, though Fresenius operates at much larger scale.

Others

  • Cytiva (Danaher): Supplies purification, filtration, and bioprocessing technologies that biosyn uses in KLH manufacturing. An ecosystem/equipment peer rather than a direct competitor, but relevant for understanding biosyn's manufacturing cost structure and GMP supply chain.

Regional players

  • Helixor Heilmittel: German-rooted biopharmaceutical company developing mistletoe-based and other complementary oncology therapies. Comparable to biosyn's German subsidiary in jurisdiction and to IMMUCOTHEL®'s bladder cancer immunotherapy positioning in the European oncology market.
  • Aguettant: European specialty injectable pharmaceutical manufacturer with trace element and electrolyte products. Directly comparable to Selenase® in product category, route of administration, and European hospital market positioning.

Direct peers

  • Bio-Techne: Supplies proteins and reagents (including antibodies and immunology research tools) used in immunotherapy and vaccine research workflows that consume KLH. Closely comparable customer base (academic and pharma immunology labs) to biosyn's research-grade KLH buyers.
  • Stellar Biotechnologies: Historically a direct competitor focused on sustainable KLH production from Megathura crenulata for immunotherapy and conjugate vaccine applications. Most directly comparable to biosyn in species, product format, and target market, though its current operating status is limited.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Biosyn compliance and trust

Trust signal

Compliance4 records

Biosyn financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biosyn leadership team

Management profile

Number of profiles

Profiles2 records

Biosyn subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Biosyn funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biosyn M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biosyn

What does Biosyn do?

Biosyn Corporation manufactures clinical/GMP and research grade Keyhole Limpet Hemocyanin (KLH) and Immunocyanin products derived from the hemolymph of Megathura crenulata (Giant Keyhole Limpet), marketed under the trade names IMMUCOTHEL®, VACMUNE®, Native KLH, and Reassociated KLH (RANKLH). The company also manufactures Selenase® (sodium selenite pentahydrate), a selenium drug product indicated for selenium deficiency and investigated in sepsis, intensive care, and other clinical settings. Products are sold as bulk and vialed clinical/research materials for immunotherapy, antibody production, vaccine adjuvant, and pharmaceutical use.

Is Biosyn a public or private company?

Biosyn is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Biosyn founded?

Biosyn was founded in 1994. It employs 11 to 50 people.

Where is Biosyn based?

Biosyn is headquartered in Carlsbad, United States, in the North America region.

How does Biosyn make money?

Three revenue lines are on record. Sales of hemocyanin/immunocyanin products are the primary driver. The others are licensed drug product sales (Selenase®) and regulatory and scientific support services.

Who are Biosyn's main competitors?

bioMérieux is listed as an emerging player. Broad incumbents are Lonza Group, Thermo Fisher Scientific, MilliporeSigma (Merck KGaA Life Science) and Fresenius Kabi. Cytiva (Danaher) is listed as an others. Regional players are Helixor Heilmittel and Aguettant. Direct peers are Bio-Techne and Stellar Biotechnologies.

Does Biosyn have an API?

No public API is recorded for Biosyn.

What industry is Biosyn in?

Biosyn's product category is Biopharmaceutical Manufacturing. Its primary akta.pro industry code is HLAMAEAD, Parasiticides & Ectoparasite Control (Flea/Tick/Heartworm). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals